[ Price : $8.95]
Federal Register Notice/Final rule: FDA withdraws approval of a Fleming Laboratories NADA for arsanilic acid Type A medicated arti...[ Price : $8.95]
FDA grants Portola Pharmaceuticals a breakthrough therapy designation for andexanet alfa, an investigational Factor Xa inhibitor a...[ Price : $8.95]
Concerned about a new marketing campaign, FDA tells 23andMe to immediately stop marketing its direct-to-consumer Saliva Collection...[ Price : $8.95]
FDA extends by three months its review of a Mallinckrodt NDA for its investigational compound Xartemis XR (oxycodone hydrochloride...[ Price : $8.95]
FDA grants priority review status to Avedro Inc. for an NDA for riboflavin ophthalmic solution/KXL system, a treatment of keratoco...[ Price : $8.95]
Repros Therapeutics says FDA has granted a face-to-face meeting to discuss pivotal efficacy studies for Androxal, an orally active...[ Price : $8.95]
Cubist Pharmaceuticals reports positive results from its Phase 3 clinical trial of antibiotic ceftolozane/tazobactam in patients w...[ Price : $8.95]
Ventrus Biosciences completes enrollment of a second Phase 3 trial of its diltiazem hydrochloride 2% cream in patients with pain r...